Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026)
Gilead Sciences (GILD) reported Goodwill & Intangibles of $24.7 billion for Q1 2026, down 10.74% on a YoY basis from $27.7 billion in Q1 2025, and down 2.36% quarter-over-quarter from $25.3 billion in Q4 2025.
Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Goodwill & Intangibles for 18 years, with the latest figure at $24.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles fell 10.74% year-over-year to $24.7 billion; the trailing twelve-month figure through Mar 2026 stood at $24.7 billion (down 10.74% YoY), and the FY2025 full-year result was $25.3 billion, down 10.51% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $24.7 billion, down from $25.3 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $38.6 billion in Q1 2022, with the low at $24.7 billion in Q1 2026.
- Historically, Goodwill & Intangibles has averaged $32.1 billion across 5 years, with a median of $31.7 billion in 2024.
- Annual changes were most pronounced in 2023 — Goodwill & Intangibles decreased 5.13% — and 2024, when it declined 18.71%.
- Gilead Sciences' Goodwill & Intangibles stood at $37.2 billion in 2022, then declined by 6.56% to $34.8 billion in 2023, then decreased by 18.71% to $28.3 billion in 2024, then decreased by 10.51% to $25.3 billion in 2025, then decreased by 2.36% to $24.7 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $24.7 billion (Q1 2026), $25.3 billion (Q4 2025), and $26.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.70 Bn |
| Dec 31, 2025 | 25.29 Bn |
| Sep 30, 2025 | 26.28 Bn |
| Jun 30, 2025 | 26.88 Bn |
| Mar 31, 2025 | 27.67 Bn |
| Dec 31, 2024 | 28.26 Bn |
| Sep 30, 2024 | 28.86 Bn |
| Jun 30, 2024 | 31.15 Bn |
| Mar 31, 2024 | 31.74 Bn |
| Dec 31, 2023 | 34.77 Bn |
| Sep 30, 2023 | 35.47 Bn |
| Jun 30, 2023 | 36.06 Bn |
| Mar 31, 2023 | 36.66 Bn |
| Dec 31, 2022 | 37.21 Bn |
| Sep 30, 2022 | 37.75 Bn |
| Jun 30, 2022 | 38.20 Bn |
| Mar 31, 2022 | 38.65 Bn |
| Dec 31, 2021 | 41.79 Bn |
| Sep 30, 2021 | 42.23 Bn |
| Jun 30, 2021 | 42.68 Bn |